Gene aspects on COPD phenotypes  by Crapo, James D.
Abstracts S3GENE ASPECTS ON COPD PHENOTYPES
James D. Crapo
National Jewish Health, Denver, Colorado, USA
E-mail address: jdc@crapodenver.com
Chronic obstructive pulmonary disease (COPD), one of the leading causes of
death world-wide, is a heterogeneous syndrome. Understanding the hetero-
geneity of COPD and subdividing it into its unique subtypes is necessary to
both define its pathogenesis and enable development of new subtype-
specific therapies. Longitudinal data to elucidate the genetic, clinical, and
radiographic determinants of disease expression and progression are
needed. The COPDGene project is attempting to: a) identify new genetic
loci that influence the development of COPD and COPD-related phenotypes;
and b) classify COPD into subtypes that can ultimately be used to develop
effective subtype-specific therapies. COPDGene is a cohort of 10,000
smokers who either have or are at risk for developing COPD. This cohort
was assembled at 21 medical centers across the United States. All subjects
have undergone inspiratory and expiratory Chest CT scans which are being
quantitatively analyzed and used in combination with clinical characteristics
to subdivide the cohort into coherent clinical/image based subtypes. A
Genome-Wide Association Analysis has been done and whole exome
sequencing is underway. Genetic analysis of case/control status has
confirmed risk for COPD to be associated with a number of genes including
HHIP, FAM-13 and nicotine addiction loci. Unique genetic associations with
specific subtypes of COPD are also being identified including associations
with risk for mild upper-lobe predominant COPD and risk for more severe,
progressive centrilobular emphysema. Lower-lobe predominant panlobular
emphysema has been long identified as associated with alpha-1 antitrypsin
deficiency. Image based subtyping of COPD has identified a large number of
subjects (both current and former smokers) who have gas trapping,
emphysema, airway inflammation and decreased quality of life, but who
do not have physiologic obstruction. These subjects would not be classified
as having COPD by traditional spiromentry based criteria. A new classifica-
tion system based on pathophysiologic subtypes of COPD is needed and can
be accomplished by integrating genetic, clinical, physiologic, and CT-based
phenotypes.
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If one aim for COPD research is to lead to improvements in symptoms and
outcomes for COPD patients then the chances of success will be maximised
by ensuring the best definition of what is COPD and clarifying if phenotypes
exist with differing potential for intervention. Airflow obstruction is an
essential requirement for COPD and using FEV1/FVC as a fixed ratio leads to
higher prevalence rates and sex bias compared to using lower limits of
normal (LLN). The airflow obstruction should then be persistent but how
best to assess this is not well defined. The presence of continuing airflow
obstruction post bronchodilator (BD) can be seen in asthma as well as
COPD. Using post BD change as a percent of predicted (PP) avoids sex bias
when defining reversibility and <9PP makes asthma less likely. A COPDphenotype of airflow obstruction plus a low FEV1 identifies more severe dis-
ease. Mortality better relates to FEV1 when expressed in relation to ‘the bot-
tom line’ such as FEV1/ht3 rather than relating it to a predicted value.
Phenotypes defined by a low gas transfer are better related to mortality
than those defined by a low Kco. This is because Kco can fall with worsening
disease, as in pure emphysema, or paradoxically increase if progressive
airway closure reduces effective alveolar volume. These points will be illus-
trated with results using long term follow up data from over 500 patients
with alpha-1 antitrypsin deficiency, 1500 patients with COPD and from
over 4000 patients with other lung diseases. In conclusion, the interests of
COPD patients will be best served by careful attention to detail in defining
the disease and its phenotypes to reduce misclassification. Only then will
studies have the best chance of identifying successful interventions.
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The 2011 revision of the GOLD document (1, 2) has in some areas been
changed substantially compared to previous versions. The new document
strongly suggests that assessment of any COPD patient should involve the
following 4 components: 1) assessment of symptoms, 2) assessment of
airflow limitation, 3) assessment of exacerbation history, and 4) assessment
of comorbidities. Instead of just evaluating stages as defined by FEV1, GOLD
now suggests a combined assessment of symptoms and risk of exacerbations.
Symptoms can be assessed by the mMRC breathlessness scale, the COPD
Assessment Test (CAT) or the Clinical COPD Questinnaire (CCQ). Patients
can be characterised as having few symptoms or many symptoms based on
either of these questionnaires. Exacerbation risk can be assessed using exac-
erbation history and spirometry (FEV1), and patients are characterised as
having either low risk or high risk of exacerbations. Patients with less than
2 exacerbations last year, no admissions because of exacerbations and an
FEV1 of 50+ % of predicted have a low risk of exacerbations. Patients with
2+ exacerbations last year, one or more admissions or an FEV1 < 50 % of pre-
dicted have a high risk of exacerbations.
This combined assessment can subsequently be used for determining
treatment, both non-pharmacological and pharmacological treatment. The
document emphasises the importance of smoking cessation and the strong
evidence base for pulmonary rehabilitation and advocates physical exercise
in all COPD patients. The document maintains that bronchodilators are the
main drugs for COPD with inhaled corticosteroids and PDE4-inhibitors being
reserved for patients at high risk of exacerbations only.
The new GOLD document also includes new chapters on management of
exacerbations and on managing COPD with comorbidities.
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